Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo IV Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

NCT06491550
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD4144- Part A, Placebo- Part A, AZD4144- Part B, Placebo- Part B, Rosuvastatin and Furosemide- Part C, Rosuvastatin, Furosemide, and AZD4144 Part C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

NCT04325035
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Istaroxime, Placebo
Drug
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3451838 in Participants With Migraine

NCT04498910
View directory record Official record
Conditions
Migraine
Interventions
LY3451838, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

NCT00538434
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years to 18 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

NCT00519285
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis
Interventions
Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 26, 2026, 2:56 PM EDT
Withdrawn Phase 4 Interventional

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures

NCT01231191
View directory record Official record
Conditions
Postoperative Pain, Intraoperative and Postoperative Opioid Requirements
Interventions
Intravenous acetaminophen, Intravenous placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NCT00591318
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions
ceftriaxone, Normal Saline
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

This is a Study to Determine the Antidepressant Effects of AZD6765

NCT00986479
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
AZD6765, Placebo to AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dysphagia Following Anterior Cervical Spine Surgery; Single Dose Steroid vs Saline (DysDexVSSal)

NCT03711474
View directory record Official record
Conditions
Dysphagia
Interventions
Dexamethasone, Saline
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT03823391
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
ABBV-3373, Placebo for ABBV-3373, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

NCT00571324
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
7 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Phase 4 Interventional Results available

Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients

NCT03040024
View directory record Official record
Conditions
Otolaryngeal Cancer
Interventions
Ketamine, Placebo, Electroencephalogram (EEG)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

NCT00435591
View directory record Official record
Conditions
Hyponatremia, Euvolemia, Hypervolemia
Interventions
Conivaptan, placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers

NCT06086613
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
AGA2115, Placebo
Drug
Lead sponsor
Angitia Incorporated Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lake Forest, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

NCT03726879
View directory record Official record
Conditions
Breast Cancer
Interventions
Atezolizumab, Placebo, Doxorubicin, Cyclophosphamide, Paclitaxel, Trastuzumab, Pertuzumab, Trastuzumab Emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Kansas City, Missouri • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 26, 2026, 2:56 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, IgAN
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
39
States / cities
Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 26, 2026, 2:56 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Silver Spring, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

NCT04110535
View directory record Official record
Conditions
Abuse, Drug
Interventions
Remimazolam, Midazolam, Saline
Drug · Other
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Phase 3 Interventional Results available

Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo

NCT01900665
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Solanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 90 Years
Enrollment
2,129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
120
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

NCT03142334
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
62
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

NCT02446899
View directory record Official record
Conditions
Active Systemic Lupus Erythematosus
Interventions
Anifrolumab, Placebo
Biological · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
35
States / cities
Covina, California • Hemet, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer

NCT00003869
View directory record Official record
Conditions
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
carboxyamidotriazole, placebo, quality-of-life assessment, laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Perioperative Intravenous Lidocaine or Epidural Anesthesia on Outcomes in Complex Spine Surgery

NCT00840996
View directory record Official record
Conditions
Spine Surgery
Interventions
Lidocaine, placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 26, 2026, 2:56 PM EDT